{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:21:05Z","timestamp":1793661665021,"version":"4.5.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970676"],"award-info":[{"award-number":["81970676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sichuan Science and Technology Program","award":["2020YFS0456"],"award-info":[{"award-number":["2020YFS0456"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objectives<\/jats:title>\n                <jats:p>Chemerin is a brand-new adipokine that has been linked to both inflammation and metabolic dysfunction. Even though a rising number of studies have connected chemerin to metabolic-associated fatty liver disease (MAFLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), this association has been controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A comprehensive literature search was undertaken up to February 1, 2022, in the PubMed, Embase, Web of Science, CNKI, WANFANG, and CBM library databases. Circulating chemerin levels were obtained and summarized using the standardized mean difference (SMD) and 95% confidence interval (CI). Subgroup and meta-regression analyses were conducted to examine the possibility of heterogeneity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 17 studies involving 2580 participants (1584 MAFLD patients and 996 controls) evaluated circulating chemerin levels in patients with MAFLD. The present study showed that higher chemerin levels were found in patients with MAFLD (SMD: 1.32; 95% CI: 0.29, 2.35) and nonalcoholic fatty liver (NAFL) (SMD: 0.75; 95% CI: 0.01, 1.50) compared to controls. However, circulating chemerin levels did not differ significantly in the following comparisons: nonalcoholic steatohepatitis (NASH) patients and controls (SMD: 0.75; 95% CI: -0.52, 2.03); NASH patients and NAFL patients (SMD: 0.16; 95% CI: -0.39, 0.70); moderate to severe steatosis and mild steatosis (SMD: 0.55; 95% CI: -0.59, 1.69); present liver fibrosis and absent liver fibrosis (SMD: 0.66; 95% CI: -0.42, 1.74); present lobular inflammation and absent lobular inflammation (SMD: 0.45; 95% CI: -0.53, 1.42); and present portal inflammation and absent portal inflammation (SMD: 1.92; 95% CI: -0.85, 4.69).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Chemerin levels were considerably greater in patients with MAFLD than in controls, despite the fact that they were not significantly linked to different liver tissue lesions of MAFLD. In different subtypes of MAFLD, in comparison to healthy controls, the chemerin levels of NAFL patients were higher, whereas, there was no obvious difference in chemerin levels between NASH patients and controls. It is possible that chemerin will be used as a biomarker in the future to track the development and progression of MAFLD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-022-01637-7","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:03:14Z","timestamp":1646218994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Qian","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"1637_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al: A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020, 73:202\u2013209. doi: https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"key":"1637_CR2","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1053\/gast.2002.33573","volume":"122","author":"JM Clark","year":"2002","unstructured":"Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002, 122:1649\u20131657. doi: https:\/\/doi.org\/10.1053\/gast.2002.33573.","journal-title":"Gastroenterology"},{"key":"1637_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016, 64:73\u201384. doi: https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"key":"1637_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, et al: Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol 2018, 69:896\u2013904. doi: https:\/\/doi.org\/10.1016\/j.jhep.2018.05.036.","journal-title":"J Hepatol"},{"key":"1637_CR5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ: Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018, 24:908\u2013922. doi: https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","journal-title":"Nat Med"},{"key":"1637_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41575-019-0239-2","volume":"17","author":"CD Byrne","year":"2020","unstructured":"Byrne CD, Targher G: What\u2019s new in NAFLD pathogenesis, biomarkers and treatment? Nat Rev Gastroenterol Hepatol 2020, 17:70\u201371. doi: https:\/\/doi.org\/10.1038\/s41575-019-0239-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1637_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","volume":"47","author":"A Lonardo","year":"2015","unstructured":"Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P: Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015, 47:181\u2013190. doi: https:\/\/doi.org\/10.1016\/j.dld.2014.09.020.","journal-title":"Dig Liver Dis"},{"key":"1637_CR8","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G: Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017, 66:1138\u20131153. doi: https:\/\/doi.org\/10.1136\/gutjnl-2017-313884.","journal-title":"Gut"},{"key":"1637_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12944-020-01288-6","volume":"19","author":"SS Liu","year":"2020","unstructured":"Liu SS, Ma XF, Zhao J, Du SX, Zhang J, Dong MZ, Xin YN: Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. Lipids Health Dis 2020, 19:118. doi: https:\/\/doi.org\/10.1186\/s12944-020-01288-6.","journal-title":"Lipids Health Dis"},{"key":"1637_CR10","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R: The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016, 64:1577\u20131586. doi: https:\/\/doi.org\/10.1002\/hep.28785.","journal-title":"Hepatology"},{"key":"1637_CR11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","volume":"49","author":"DC Rockey","year":"2009","unstructured":"Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD: Liver biopsy. Hepatology 2009, 49:1017\u20131044. doi: https:\/\/doi.org\/10.1002\/hep.22742.","journal-title":"Hepatology"},{"key":"1637_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/1523-1747.ep12276660","volume":"109","author":"S Nagpal","year":"1997","unstructured":"Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, Teng M, Duvic M, Chandraratna RA: Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol 1997, 109:91\u201395. doi: https:\/\/doi.org\/10.1111\/1523-1747.ep12276660.","journal-title":"J Invest Dermatol"},{"key":"1637_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.20030382","volume":"198","author":"V Wittamer","year":"2003","unstructured":"Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Br\u00e9zillon S, Tyldesley R, Blanpain C, Detheux M, et al: Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003, 198:977\u2013985. doi: https:\/\/doi.org\/10.1084\/jem.20030382.","journal-title":"J Exp Med"},{"key":"1637_CR14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.tem.2010.08.001","volume":"21","author":"MC Ernst","year":"2010","unstructured":"Ernst MC, Sinal CJ: Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 2010, 21:660\u2013667. doi: https:\/\/doi.org\/10.1016\/j.tem.2010.08.001.","journal-title":"Trends Endocrinol Metab"},{"key":"1637_CR15","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1210\/jc.2010-0042","volume":"95","author":"K Bozaoglu","year":"2010","unstructured":"Bozaoglu K, Curran JE, Stocker CJ, Zaibi MS, Segal D, Konstantopoulos N, Morrison S, Carless M, Dyer TD, Cole SA, et al: Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab 2010, 95:2476\u20132485. doi: https:\/\/doi.org\/10.1210\/jc.2010-0042.","journal-title":"J Clin Endocrinol Metab"},{"key":"1637_CR16","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.2337\/db09-0277","volume":"58","author":"H Sell","year":"2009","unstructured":"Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, Arner P, Eckel J: Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009, 58:2731\u20132740. doi: https:\/\/doi.org\/10.2337\/db09-0277.","journal-title":"Diabetes"},{"key":"1637_CR17","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.2337\/db10-0362","volume":"59","author":"M Becker","year":"2010","unstructured":"Becker M, Rabe K, Lebherz C, Zugwurst J, G\u00f6ke B, Parhofer KG, Lehrke M, Broedl UC: Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes 2010, 59:2898\u20132903. doi: https:\/\/doi.org\/10.2337\/db10-0362.","journal-title":"Diabetes"},{"key":"1637_CR18","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1210\/en.2009-1098","volume":"151","author":"MC Ernst","year":"2010","unstructured":"Ernst MC, Issa M, Goralski KB, Sinal CJ: Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology 2010, 151:1998\u20132007. doi: https:\/\/doi.org\/10.1210\/en.2009-1098.","journal-title":"Endocrinology"},{"key":"1637_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/aji.12405","volume":"74","author":"CH Jin","year":"2015","unstructured":"Jin CH, Yi KW, Ha YR, Shin JH, Park HT, Kim T, Hur JY: Chemerin Expression in the Peritoneal Fluid, Serum, and Ovarian Endometrioma of Women with Endometriosis. Am J Reprod Immunol 2015, 74:379\u2013386. doi: https:\/\/doi.org\/10.1111\/aji.12405.","journal-title":"Am J Reprod Immunol"},{"key":"1637_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2015.05.018","volume":"448","author":"O Zhang","year":"2015","unstructured":"Zhang O, Ji Q, Lin Y, Wang Z, Huang Y, Lu W, Liu X, Zhang J, Liu Y, Zhou YJ: Circulating chemerin levels elevated in dilated cardiomyopathy patients with overt heart failure. Clin Chim Acta 2015, 448:27\u201332. doi: https:\/\/doi.org\/10.1016\/j.cca.2015.05.018.","journal-title":"Clin Chim Acta"},{"key":"1637_CR21","doi-asserted-by":"publisher","unstructured":"Sochal M, Fichna J, Gabryelska A, Talar-Wojnarowska R, Bia\u0142asiewicz P, Ma\u0142ecka-Wojciesko E. Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy. J Clin Med.\u00a02021;10:4615.\u00a0\u00a0https:\/\/doi.org\/10.3390\/jcm10194615.","DOI":"10.3390\/jcm10194615"},{"key":"1637_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.26672","volume":"59","author":"AL Birkenfeld","year":"2014","unstructured":"Birkenfeld AL, Shulman GI: Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014, 59:713\u2013723. doi: https:\/\/doi.org\/10.1002\/hep.26672.","journal-title":"Hepatology"},{"key":"1637_CR23","doi-asserted-by":"publisher","unstructured":"Gao B, Tsukamoto H. Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe? Gastroenterology.\u00a02016;150:1704\u20139.\u00a0https:\/\/doi.org\/10.1053\/j.gastro.2016.01.025.","DOI":"10.1053\/j.gastro.2016.01.025"},{"key":"1637_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/00365520903443852","volume":"45","author":"M Kukla","year":"2010","unstructured":"Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, Ciupinska-Kajor M, Berdowska A, Wozniak-Grygiel E, Buldak R: Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 2010, 45:235\u2013242. doi: https:\/\/doi.org\/10.3109\/00365520903443852.","journal-title":"Scand J Gastroenterol"},{"key":"1637_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/00365521.2010.516452","volume":"46","author":"Y Yilmaz","year":"2011","unstructured":"Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, Celikel CA, Imeryuz N, Kalayci C, Avsar E: Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011, 46:91\u201397. doi: https:\/\/doi.org\/10.3109\/00365521.2010.516452.","journal-title":"Scand J Gastroenterol"},{"key":"1637_CR26","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.7754\/clin.lab.2015.150211","volume":"61","author":"X Zhuang","year":"2015","unstructured":"Zhuang X, Sun F, Li L, Jiang D, Li X, Sun A, Pan Z, Lou N, Zhang L, Lou F: Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Clin Lab 2015, 61:1409\u20131414. doi: https:\/\/doi.org\/10.7754\/clin.lab.2015.150211.","journal-title":"Clin Lab"},{"key":"1637_CR27","doi-asserted-by":"publisher","first-page":"862","DOI":"10.5604\/16652681.1222102","volume":"15","author":"A Zwolak","year":"2016","unstructured":"Zwolak A, Szuster-Ciesielska A, Daniluk J, Semeniuk J, Kandefer-Szerszen M: Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease. Ann Hepatol 2016, 15:862\u2013869. doi: https:\/\/doi.org\/10.5604\/16652681.1222102.","journal-title":"Ann Hepatol"},{"key":"1637_CR28","first-page":"64","volume":"14","author":"M Lai","year":"2017","unstructured":"Lai M, Zhang S, Jin Q, Huang J, Xu J, Zeng H, Qin Y, Wu D, Ge B, Xu G, Wu P: The correlation between serum levels of IL-11\u03b2, IL-8 and chemerinin patients with non-alcoholic fatty liver disease. Pract Clin Med 2017, 14:64\u201366.","journal-title":"Pract Clin Med"},{"key":"1637_CR29","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.3892\/etm.2018.5753","volume":"15","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Wang J, Wang H: Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus. Exp Ther Med 2018, 15:2936\u20132940. doi: https:\/\/doi.org\/10.3892\/etm.2018.5753.","journal-title":"Exp Ther Med"},{"key":"1637_CR30","unstructured":"Sahar MI, Naglaa AE, Zeinab HES, Aida AAEH, Inass HA, Azza AA. Chemerin and vaspin as noninvasive biomarkers in the pathogenesis and diagnosis of non- alcoholic fatty liver disease. Am J Med Sci. 2019;9:7."},{"key":"1637_CR31","first-page":"82","volume":"18","author":"S Hang","year":"2019","unstructured":"Hang S, Shen H, Chen M: Correlation of serum SHGB levels with insulin sensitivity, lipid metabolism oxidative stress in patients with nonalcoholic fatty liver disese. J Clin Exp Med 2019, 18:82\u201385.","journal-title":"J Clin Exp Med"},{"key":"1637_CR32","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.21608\/ejhm.2021.177253","volume":"84","author":"G Mohamed","year":"2021","unstructured":"Mohamed G, Salama MM, Byoumy E, Mohamed A, Ibrahim W, El-shafie A, Abdallah M: Chemerin As A Non-Invasive Serum Marker for Non-Alcoholic Fatty Liver Disease. The Egyptian Journal of Hospital Medicine 2021, 84:1786\u20131790. doi: https:\/\/doi.org\/10.21608\/ejhm.2021.177253.","journal-title":"The Egyptian Journal of Hospital Medicine"},{"key":"1637_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.14000\/j.cnki.issn.1008-1704.2021.04.023","volume":"26","author":"H Gao","year":"2021","unstructured":"Gao H, Yang D, Liang H, Wang X, Wang Y, Chen B: Association of serum Chemerin levels and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. Chin Hepatol 2021, 26:429\u2013434. doi: https:\/\/doi.org\/10.14000\/j.cnki.issn.1008-1704.2021.04.023.","journal-title":"Chin Hepatol"},{"key":"1637_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3969\/j.issn.1672-9463.2021.08.006","volume":"23","author":"D Xing","year":"2021","unstructured":"Xing D, Sun Y, Yu L, Su S, Zhang H: Changes of serum Chemerin level in patients with nonalcoholic fatty liver disease and its relationship with insulin resistance and inflammation. Mod Med J Chin 2021, 23:23\u201326. doi: https:\/\/doi.org\/10.3969\/j.issn.1672-9463.2021.08.006.","journal-title":"Mod Med J Chin"},{"key":"1637_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s11033-013-2977-5","volume":"41","author":"Z Ye","year":"2014","unstructured":"Ye Z, Wang S, Yang Z, He M, Zhang S, Zhang W, Wen J, Li Q, Huang Y, Wang X, et al: Serum lipocalin-2, cathepsin S and chemerin levels and nonalcoholic fatty liver disease. Mol Biol Rep 2014, 41:1317\u20131323. doi: https:\/\/doi.org\/10.1007\/s11033-013-2977-5.","journal-title":"Mol Biol Rep"},{"key":"1637_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.metabol.2013.09.013","volume":"63","author":"SA Polyzos","year":"2014","unstructured":"Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS: Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014, 63:207\u2013217. doi: https:\/\/doi.org\/10.1016\/j.metabol.2013.09.013.","journal-title":"Metabolism"},{"key":"1637_CR37","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/oby.21674","volume":"24","author":"M Bekaert","year":"2016","unstructured":"Bekaert M, Ouwens DM, H\u00f6rbelt T, Van de Velde F, Fahlbusch P, Herzfeld de Wiza D, Van Nieuwenhove Y, Calders P, Praet M, Hoorens A, et al: Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity. Obesity (Silver Spring) 2016, 24:2544\u20132552. doi: https:\/\/doi.org\/10.1002\/oby.21674.","journal-title":"Obesity (Silver Spring)"},{"key":"1637_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/eci.12695","volume":"47","author":"R Pohl","year":"2017","unstructured":"Pohl R, Haberl EM, Rein-Fischboeck L, Zimny S, Neumann M, Aslanidis C, Schacherer D, Krautbauer S, Eisinger K, Weiss TS, Buechler C: Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. Eur J Clin Invest 2017, 47:7\u201318. doi: https:\/\/doi.org\/10.1111\/eci.12695.","journal-title":"Eur J Clin Invest"},{"key":"1637_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5114\/pjp.2017.69687","volume":"68","author":"M Kajor","year":"2017","unstructured":"Kajor M, Kukla M, Waluga M, Liszka \u0141, Dyaczy\u0144ski M, Kowalski G, \u017b\u0105d\u0142o D, Berdowska A, Chapu\u0142a M, Kostrz\u0105b-Zdebel A, et al: Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease. Pol J Pathol 2017, 68:117\u2013127. doi: https:\/\/doi.org\/10.5114\/pjp.2017.69687.","journal-title":"Pol J Pathol"},{"key":"1637_CR40","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Bmj 2021, 372:n160. doi: https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"Bmj"},{"key":"1637_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.envint.2018.11.004","volume":"122","author":"RL Morgan","year":"2019","unstructured":"Morgan RL, Thayer KA, Santesso N, Holloway AC, Blain R, Eftim SE, Goldstone AE, Ross P, Ansari M, Akl EA, et al: A risk of bias instrument for non-randomized studies of exposures: A users\u2019 guide to its application in the context of GRADE. Environ Int 2019, 122:168\u2013184. doi: https:\/\/doi.org\/10.1016\/j.envint.2018.11.004.","journal-title":"Environ Int"},{"key":"1637_CR42","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, et al: Grading quality of evidence and strength of recommendations. Bmj 2004, 328:1490. doi: https:\/\/doi.org\/10.1136\/bmj.328.7454.1490.","journal-title":"Bmj"},{"key":"1637_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13. doi: https:\/\/doi.org\/10.1186\/1471-2288-5-13.","journal-title":"BMC Med Res Methodol"},{"key":"1637_CR44","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2009-2374","volume":"95","author":"H Sell","year":"2010","unstructured":"Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, Tordjman J, Eckel J, Cl\u00e9ment K: Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2010, 95:2892\u20132896. doi: https:\/\/doi.org\/10.1210\/jc.2009-2374.","journal-title":"J Clin Endocrinol Metab"},{"key":"1637_CR45","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1530\/ec-19-0300","volume":"8","author":"LM Levin","year":"2019","unstructured":"Levin LM, V\u00f6lzke H, Lerch MM, K\u00fchn JP, Nauck M, Friedrich N, Zylla S: Associations of circulating chemerin and adiponectin concentrations with hepatic steatosis. Endocr Connect 2019, 8:1097\u20131107. doi: https:\/\/doi.org\/10.1530\/ec-19-0300.","journal-title":"Endocr Connect"},{"key":"1637_CR46","doi-asserted-by":"publisher","first-page":"119530","DOI":"10.1016\/j.lfs.2021.119530","volume":"278","author":"L Zhu","year":"2021","unstructured":"Zhu L, Huang J, Wang Y, Yang Z, Chen X: Chemerin causes lipid metabolic imbalance and induces passive lipid accumulation in human hepatoma cell line via the receptor GPR1. Life Sci 2021, 278:119530. doi: https:\/\/doi.org\/10.1016\/j.lfs.2021.119530.","journal-title":"Life Sci"},{"key":"1637_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12944-020-01378-5","volume":"19","author":"J Jia","year":"2020","unstructured":"Jia J, Yu F, Xiong Y, Wei W, Ma H, Nisi F, Song X, Yang L, Wang D, Yuan G, Zhou H: Chemerin enhances the adhesion and migration of human endothelial progenitor cells and increases lipid accumulation in mice with atherosclerosis. Lipids Health Dis 2020, 19:207. doi: https:\/\/doi.org\/10.1186\/s12944-020-01378-5.","journal-title":"Lipids Health Dis"},{"key":"1637_CR48","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.3748\/wjg.v16.i37.4652","volume":"16","author":"YT Zhan","year":"2010","unstructured":"Zhan YT, An W: Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J Gastroenterol 2010, 16:4652\u20134660. doi: https:\/\/doi.org\/10.3748\/wjg.v16.i37.4652.","journal-title":"World J Gastroenterol"},{"key":"1637_CR49","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/obr.12009","volume":"14","author":"JL Rourke","year":"2013","unstructured":"Rourke JL, Dranse HJ, Sinal CJ: Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev 2013, 14:245\u2013262. doi: https:\/\/doi.org\/10.1111\/obr.12009.","journal-title":"Obes Rev"},{"key":"1637_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.atherosclerosis.2017.01.003","volume":"257","author":"E Ammirati","year":"2017","unstructured":"Ammirati E, Fogacci F: Clinical relevance of biomarkers for the identification of patients with carotid atherosclerotic plaque: Potential role and limitations of cysteine protease legumain. Atherosclerosis 2017, 257:248\u2013249. doi: https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.01.003.","journal-title":"Atherosclerosis"},{"key":"1637_CR51","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/atvbaha.115.306741","volume":"36","author":"K Gasbarrino","year":"2016","unstructured":"Gasbarrino K, Mantzoros C, Gorgui J, Veinot JP, Lai C, Daskalopoulou SS: Circulating Chemerin Is Associated With Carotid Plaque Instability, Whereas Resistin Is Related to Cerebrovascular Symptomatology. Arterioscler Thromb Vasc Biol 2016, 36:1670\u20131678. doi: https:\/\/doi.org\/10.1161\/atvbaha.115.306741.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1637_CR52","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20081736","volume":"205","author":"T Yoshimura","year":"2008","unstructured":"Yoshimura T, Oppenheim JJ: Chemerin reveals its chimeric nature. J Exp Med 2008, 205:2187\u20132190. doi: https:\/\/doi.org\/10.1084\/jem.20081736.","journal-title":"J Exp Med"},{"key":"1637_CR53","doi-asserted-by":"publisher","first-page":"701915","DOI":"10.1155\/2014\/701915","volume":"2014","author":"S Coimbra","year":"2014","unstructured":"Coimbra S, Brand\u00e3o Proen\u00e7a J, Santos-Silva A, Neuparth MJ: Adiponectin, leptin, and chemerin in elderly patients with type 2 diabetes mellitus: a close linkage with obesity and length of the disease. Biomed Res Int 2014, 2014:701915. doi: https:\/\/doi.org\/10.1155\/2014\/701915.","journal-title":"Biomed Res Int"},{"key":"1637_CR54","doi-asserted-by":"publisher","first-page":"e012091","DOI":"10.1161\/jaha.119.012091","volume":"8","author":"X Zhou","year":"2019","unstructured":"Zhou X, Tao Y, Chen Y, Xu W, Qian Z, Lu X: Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure. J Am Heart Assoc 2019, 8:e012091. doi: https:\/\/doi.org\/10.1161\/jaha.119.012091.","journal-title":"J Am Heart Assoc"},{"key":"1637_CR55","doi-asserted-by":"publisher","first-page":"R193-r205","DOI":"10.1530\/eje-20-1410","volume":"184","author":"DP Sonne","year":"2021","unstructured":"Sonne DP: MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases. Eur J Endocrinol 2021, 184:R193-r205. doi: https:\/\/doi.org\/10.1530\/eje-20-1410.","journal-title":"Eur J Endocrinol"},{"key":"1637_CR56","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1210\/en.2012-2126","volume":"154","author":"Y Deng","year":"2013","unstructured":"Deng Y, Wang H, Lu Y, Liu S, Zhang Q, Huang J, Zhu R, Yang J, Zhang R, Zhang D, et al: Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis. Endocrinology 2013, 154:1794\u20131801. doi: https:\/\/doi.org\/10.1210\/en.2012-2126.","journal-title":"Endocrinology"},{"key":"1637_CR57","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","volume":"4","author":"ZX Yang","year":"2010","unstructured":"Yang ZX, Shen W, Sun H: Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int 2010, 4:741\u2013748. doi: https:\/\/doi.org\/10.1007\/s12072-010-9202-6.","journal-title":"Hepatol Int"},{"key":"1637_CR58","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2013.12.003","volume":"60","author":"X Xiong","year":"2014","unstructured":"Xiong X, Wang X, Lu Y, Wang E, Zhang Z, Yang J, Zhang H, Li X: Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatol 2014, 60:847\u2013854. doi: https:\/\/doi.org\/10.1016\/j.jhep.2013.12.003.","journal-title":"J Hepatol"},{"key":"1637_CR59","first-page":"879","volume":"57","author":"W Lin","year":"2011","unstructured":"Lin W, Chen YL, Jiang L, Chen JK: Reduced expression of chemerin is associated with a poor prognosis and a lowed infiltration of both dendritic cells and natural killer cells in human hepatocellular carcinoma. Clin Lab 2011, 57:879\u2013885.","journal-title":"Clin Lab"},{"key":"1637_CR60","doi-asserted-by":"publisher","unstructured":"Haberl EM, Feder S, Pohl R, Rein-Fischboeck L, D\u00fcrholz K, Eichelberger L, Wanninger J, Weiss TS, Buechler C. Chemerin Is Induced in Non-Alcoholic Fatty Liver Disease and Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel). 2020;12:2967. https:\/\/doi.org\/10.3390\/cancers12102967.","DOI":"10.3390\/cancers12102967"},{"key":"1637_CR61","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.21873\/anticanres.12507","volume":"38","author":"EM Haberl","year":"2018","unstructured":"Haberl EM, Pohl R, Rein-Fischboeck L, Feder S, Sinal CJ, Buechler C: Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis. Anticancer Res 2018, 38:2649\u20132657. doi: https:\/\/doi.org\/10.21873\/anticanres.12507.","journal-title":"Anticancer Res"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-022-01637-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-022-01637-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-022-01637-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:08:52Z","timestamp":1646219332000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-022-01637-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1186\/s12944-022-01637-7","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}